Daratumumab is safe and induces a rapid hematological response in light-chain amyloidosis with severe cardiac impairment
- Resource Type
- Source
- Leukemia & Lymphoma. 62:979-983
- Subject
Cancer Research Pathology medicine.medical_specialty Chemistry Amyloidosis Organ dysfunction Antibodies, Monoclonal Daratumumab Hematological response Hematology Immunoglobulin light chain medicine.disease 03 medical and health sciences 0302 clinical medicine Oncology 030220 oncology & carcinogenesis Plasma cell disorder medicine Extracellular Humans medicine.symptom Deposition (chemistry) 030215 immunology - Language
- ISSN
- 1029-2403
1042-8194